DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NOV 20 2006

1805 6 NOV 21 A9:51

Elizabeth A. Marro
Senior Director, Regulatory Affairs and Quality Assurance
West-ward Pharmaceutical Corp.
465 Industrial Way West
Eatontown, NJ 07724

Re: Docket No. 2006P-0218/CP1

Dear Ms. Marro:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition submitted on May 24, 2006. Your petition requests that the Agency determine whether Triamcinolone Diacetate Suspension, 40 mg/mL (NDA 12-802) has been voluntarily withdrawn from distribution and sale for safety or efficacy reasons.

FDA has been unable to reach a decision on your petition due to the need to address other Agency priorities. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as possible given the numerous demands on the Agency's resources.

Sincerely,

Nancy E. Boockes

for Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

2006P-0218

LET 1